GB0004887D0 — Chemical compounds
Assigned to AstraZeneca UK Ltd · Expires 2000-04-19 · 26y expired
What this patent protects
Pyrimidine derivatives of formula (I) wherein Q<SUB>1</SUB>, Q<SUB>2</SUB>, G and R<SUP>1 </SUP>are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture,…
USPTO Abstract
Pyrimidine derivatives of formula (I) wherein Q<SUB>1</SUB>, Q<SUB>2</SUB>, G and R<SUP>1 </SUP>are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.